التفاصيل البيبلوغرافية
| العنوان: |
Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma [Dataset] |
| المؤلفون: |
Costa, Luciano J., Hari, Parameswaran, Berdeja, Jesús G., Stefano, Valerio De, Gay, Francesca, Hooper, Becky, Bartlett, Meaghan, Haltner, Anja, Rosta, Emily, Kumar, Shaji, Martin, Thomas, Mateos, Maria Victoria, Moreau, Philippe, Usmani, Saad Z., Olyslager, Yunsi, Schecter, Jordan M., Roccia, Tito, Garrett, Ashraf, Lee, Sam, Nesheiwat, Tonia, Pacaud, Lida, Zhou, Changwei, Samjoo, Imtiaz A., Lin, Yi, Dielsl, Joris, Valluri, Satish, Weisel, Katja C. |
| بيانات النشر: |
Figshare |
| سنة النشر: |
2022 |
| مصطلحات موضوعية: |
Relapsed or refractory multiple myeloma, Ciltacabtagene autoleucel, CAR-T, Triple-class exposed, CARTITUDE-1, Meta-analysis, stat, psy |
| الوصف: |
Figure A.1: Selection of Comparator Arms for ITC Analyses Figure A.2: Results of sensitivity analyses with OIs removed for OS at all (A) and first (B) index dates Figure A.3: Results of sensitivity analyses with LocoMMotion removed for OS at all (A) and first (B) index dates, and PF at first index dates (C) Table A.1: Characteristics of Data Sources for PCT arms in ITCs Table A.2: Published ITC Results and Augmented Results Included in Meta-analyses (All Index Dates) Table A.3: Published ITC Results and Augmented Results Included in Meta-analyses (First Index Dates) Table A.4: Baseline Covariates After Adjustment (mITT Populations; All Index Dates) Table A.5: Baseline Covariates After Adjustment (mITT Populations; First Index Dates) Table A.6: Outcome Definitions in ITC Analyses ; [Objective]: In the absence of head-to-head trials, indirect treatment comparisons (ITCs) between ciltacabtagene autoleucel (cilta-cel; in CARTITUDE-1) and treatments used in real-world clinical practice (physician’s choice of treatment [PCT]), were previously conducted. We conducted multiple meta-analyses using available ITC data to consolidate the effectiveness of cilta-cel versus PCT for patients with triple-class exposed relapsed or refractory multiple myeloma (RRMM). [Methods]: Five ITCs were assessed for similarity to ensure robust comparisons using meta-analysis. Effectiveness outcomes were overall survival (OS), progression-free survival (PFS), time to next treatment (TTNT), and overall response rate (ORR). A robust variance estimator was used to account for the use of CARTITUDE-1 in each pairwise ITC. Analyses were conducted in both treated and enrolled populations of CARTITUDE-1. [Results]: Four ITCs were combined for evaluation of OS. Results were statistically significantly in favor of cilta-cel versus PCT in treated patients (hazard ratio [HR]: 0.24, 95% confidence interval [CI]: 0.22–0.26). Three ITCs were combined for evaluation of PFS and TTNT. Cilta-cel reduced the risk of progression and receiving a subsequent . |
| نوع الوثيقة: |
dataset |
| اللغة: |
English |
| العلاقة: |
http://hdl.handle.net/10261/329696Test |
| الإتاحة: |
http://hdl.handle.net/10261/329696Test |
| حقوق: |
undefined |
| رقم الانضمام: |
edsbas.124AC33F |
| قاعدة البيانات: |
BASE |
